Takeda Pharmaceutical Company Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Takeda Pharmaceutical Company Limited generated cash of $716,344,000,000, which is less than the previous year. Cash used in financing activities reached the amount of -$354,416,000,000 last year. Net change in cash is therefore -$75,730,000,000.
Cash Flow
| 2014 | 148.33B | -158.61B | 101.44B |
|---|---|---|---|
| 2015 | 182.51B | 91.34B | -300.99B |
| 2016 | 25.49B | -71.20B | -124.83B |
| 2017 | 261.36B | -655.69B | 289.89B |
| 2018 | 377.85B | -93.34B | -326.22B |
| 2019 | 328.47B | -2.83T | 2.94T |
| 2020 | 669.75B | 292.11B | -1.00T |
| 2021 | 1.01T | 393.53B | -1.08T |
| 2022 | 1.12T | -198.12B | -1.07T |
| 2024 | 716.34B | -463.86B | -354.41B |
TAK Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 533.53B | 966.22B | 637.61B | 702.72B | 294.97B | 341.25B | 451.42B | 655.24B | 666.04B | 545.58B |
Operating activities | ||||||||||
Net income | 144.06B | 230.16B | 376.17B | 44.29B | 109.01B | 186.70B | 115.51B | 83.48B | -143.03B | 109.55B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 728.00B | 583.15B | 559.67B | 583.64B | 272.44B | 182.12B | 222.78B | 197.38B | 260.95B | 215.74B |
Stock-based compensation expense | 70.87B | 43.37B | 37.66B | 29.12B | 20.08B | 18.61B | 17.41B | 14.71B | 20.35B | 0 |
| Deferred income tax benefit | 70.87B | 43.37B | 37.66B | 29.12B | 20.08B | 18.61B | 17.41B | 14.71B | 20.35B | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 15.10B | 127.29B | -9.31B | -34.82B | -13.38B | -647M | -37.31B | 12.37B | -32.51B | -42.50B |
Inventories | -115.74B | -46.14B | 25.97B | 137.49B | 58.67B | 13.71B | 3.88B | -6.84B | -14.54B | -16.91B |
Accounts payable | -9.89B | 125.15B | 36.62B | -29.93B | -16.41B | 6.86B | 42.55B | 17.91B | -7.08B | -42.32B |
Cash generated by operating activities | 716.34B | 1.12T | 1.01T | 669.75B | 328.47B | 377.85B | 261.36B | 25.49B | 182.51B | 148.33B |
Investing activities | ||||||||||
Purchases Of Investments | -40.06B | -8.34B | -12.59B | -7.55B | -17.09B | -88.65B | -82.10B | -40.01B | -3.57B | -141.68B |
Investments In Property Plant And Equipment | -175.42B | -186.03B | -236.46B | -217.71B | -134.11B | -128.26B | -112.02B | -84.85B | -108.71B | -78.51B |
Acquisitions Net | -4.73B | -21.47B | 530.38B | 456.65B | -2.87T | 56.75B | -524.73B | -7.05B | -20.43B | -3.34B |
Cash generated by investing activities | -463.86B | -198.12B | 393.53B | 292.11B | -2.83T | -93.34B | -655.69B | -71.20B | 91.34B | -158.61B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 1.07T | 0 | 0 | -18.84B | 0 | 145.10B | 0 | 0 |
Payments for dividends | -287.18B | -283.66B | -283.35B | -282.58B | -142.95B | -141.89B | -141.68B | -141.53B | -141.63B | -142.13B |
Repurchases of common stock | -2.32B | -77.53B | -2.14B | -3.73B | -1.17B | -18.75B | -23.11B | -22.34B | -17.58B | 0 |
Repayments of term debt | 1.51B | -600.47B | -1.84T | -234.86B | 3.16T | -142.65B | 471.42B | -100.01B | -119.49B | -167M |
Cash used in financing activities | -354.41B | -1.07T | -1.08T | -1.00T | 2.94T | -326.22B | 289.89B | -124.83B | -300.99B | 101.44B |
Net Change In Cash | -75.73B | -116.52B | 328.60B | -65.10B | 407.12B | -46.73B | -131.97B | -203.81B | -10.80B | 120.46B |
Cash at end of period | 457.8B | 849.69B | 966.22B | 637.61B | 702.09B | 294.52B | 319.45B | 451.42B | 655.24B | 666.04B |
| Data source | Data source | Data source | Data source |